Abstract

DEVELOPMENTS IN THE DELIVERY OF SULFASALAZINE: IMPROVING THE EFFECTIVENESS OF TREATMENT FOR INFLAMMATORY BOWEL DISEASE BY USING SPRAY DRYING TECHNIQUE AND PREFORMULATION STUDY OF SULFASALAZINE

Puneet Kumar, Aman Thakur, Aman Kumar, Amandeep Kaur*, Dr. Naresh Singh Gill

.

Abstract

Inflammation of the gastrointestinal tract is caused by abnormal immune responses that are triggered by inheritance and environmental factors. 5-ASA has anti-inflammatory effects on the colonic mucosa once sulfasalazine is broken down into its active ingredients in the colon. Sulfasalazine's capacity to control the immune response and reduce inflammation is thought to be the reason for its therapeutic success in inflammatory bowel disease (IBD), however its precise mechanism is still unclear. The medication is most effective in keeping UC patients in remission and, to a lesser extent, CD patients. Sulfasalazine's physicochemical characteristics such as color, odor, melting point, and solubility are essential for creating potent formulations in preformulation investigations. The medication is identified and characterized using methods such as Fourier-transform infrared (FTIR) spectroscopy and UV spectrophotometry. The goal of developing Eudragit microparticles coated with sulfasalazine by spray drying techniques is to improve medication delivery and bioavailability. To guarantee their quality and effectiveness, these microparticles go through a thorough in vitro characterization process that includes optical microscopy, SEM, and zeta potential examination. In summary, sulfasalazine continues to be a vital component of IBD treatment, providing remarkable advantages in reducing inflammation and preserving remission. Its novel delivery methods, like microparticles, and ongoing pharmacokinetics research have the potential to improve patient outcomes in the treatment of inflammatory bowel disease.

Keywords: Sulfasalazine, IBD, Microparticle, Eudragit, Spray drying.